Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 2

A common variant in the adiponectin gene on weight loss and body composition under sibutramine therapy in obesity

Authors Hsiao T, Wu LS, Huang S, Lin E

Published 22 June 2010 Volume 2010:2 Pages 105—110


Review by Single anonymous peer review

Peer reviewer comments 2

Tun-Jen Hsiao1, Lawrence Shih-Hsin Wu3, Shih-Yi Huang2, Eugene Lin3

1College of Public Health and Nutrition, 2School of Nutrition and Health Sciences, Taipei Medical University, Taipei, Taiwan; 3Vita Genomics, Inc., Taipei, Taiwan

Abstract: In this study, we aimed to explore whether a common single nucleotide polymorphism (SNP), rs266729 (-11,377C > G), in the adiponectin C1Q and collagen domain containing (ADIPOQ) gene could influence weight reduction and fat change under sibutramine therapy in an obese population. There were 131 obese Taiwanese patients, including 44 in the placebo group and 87 in the sibutramine (10 mg daily) group. We assessed the measures of weight loss and body fat reduction at the end of the 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and baseline percent body fat as covariates. By comparing the placebo and sibutramine groups with ANCOVA, our data revealed a strong effect of sibutramine on percent body fat loss (1.9 ± 0.3 vs 4.6 ± 0.5%; P < 0.001) and on weight reduction (2.8 ± 2.0 vs 7.9 ± 1.6 kg; P < 0.001) for subjects with the CC genotype. On the contrary, sibutramine had no significant effect on percent body fat loss or on weight loss in the GG and GC individuals. The results suggest that the SNP rs266729 of the ADIPOQ gene may contribute to weight reduction and fat loss in response to sibutramine therapy in Taiwanese obese patients.

Keywords: body fat, obesity, sibutramine, single nucleotide polymorphisms, weight loss

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.